Medisafe 1 Technologies Advancing Negotiations to Acquire Additional Lifesaving Medical Technologies

Jan 30, 2012, 08:30 ET from Medisafe 1 Technologies Corp.

JERUSALEM, January 30, 2012 /PRNewswire/ --

Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company is expanding efforts to acquire companies with commercial-stage technologies that augment its existing commercial product line.

Business development efforts are underway to acquire companies with medical devices and / or lifesaving technologies that are already revenue generating.  

"Medisafe 1 Technologies continues its efforts to become a leading developer of lifesaving medical technology," said Jacob Elhadad, CEO of Medisafe 1 Technologies Corp. "We are now in the market for companies that have already proven an ability to generate revenues with medical technologies. These technologies will compliment Medisafe 1 Technologies' patented syringe locking device and transfusion bag locking device that have already proven to be commercially-viable."

About Medisafe 1 Technologies
Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle.  Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.

Forward-Looking Statements
This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated.  Medisafe 1 Technologies Corp. public filings may be viewed at

Jacob Elhadad

SOURCE Medisafe 1 Technologies Corp.